The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia.
b-catenin is dynamically stored and cleared in multiple myeloma by the proteasome--aggresome--autophagosome--lysosome pathway Multiple myeloma (MM) is a malignant proliferation of plasma cells (PCs) in the bone marrow (BM). Activation of the canonical WNT/b-catenin signaling pathway is a frequent event in MM; 1 --4 however, the molecular mechanisms underlying this phenomenon remain unknown. In contrast to most epithelial cancers, MM lacks mutations in critical components of this pathway, suggesting that deregulated post-translational mechanisms contribute to the aberrant expression of WNT pathway proteins. 1, 5 We and others have documented the overexpression of the central WNT signaling molecule, b-catenin, in a majority of MM PCs as compared with normal PCs. 1 --3,6,7 Post-translational regulation of b-catenin is typically mediated through phosphorylation events that tag the protein for ubiquitination and degradation through the 26S proteasome. In most cellular contexts, the ubiquitin --proteasome system (UPS) is sufficient to handle normal protein synthesis, misfolding and turnover; 8 however, exceeding the capacity of the UPS causes polypeptides to accumulate in cytosolic aggregates near the perinuclear microtubule organizing center. Continued stress on the UPS causes additional protein aggregates to amass, forming a dense structural assembly termed the aggresome. 9 Aggresomes recruit additional protein catabolic machinery to aid in the unfolding of compacted proteins for proteasomal or autophagosomal/lysosomal removal. 10 Thus, aggresome formation provides a reserve protein processing unit to the proteasome to eliminate unwanted proteins.
To determine the cellular localization of b-catenin, we first performed immunofluorescence (IFC) and immunohistochemical (IHC) analyses in MM cells using an antibody against this key signaling molecule. Consistent with prior reports, most cell lines showed diffused distribution of b-catenin within the cytoplasm and punctuated signals within the nucleus (Figure 1a) . 1, 2, 6 However, strong b-catenin signal was also observed in distinct perinuclear aggregates from a subpopulation of cultured MM cell lines (Figure 1a) . In order to delineate the identity of these structures, we performed double IFC analysis that demonstrated colocalization of the b-catenin signal with known aggresomal markers such as HDAC6, ubiquitin, vimentin and g-tubulin ( Figure 1b and data not shown). 9, 11 However, the expression of Golgi body markers Giantin and 58 K as well as ER marker Calnexin was distinctly different from that of the aggresome (Figures 1c and d) . Scanning electron microscopy (SEM) further confirmed these findings ( Figure 1e and Supplementary Figure 1) .
We suspected that b-catenin could be used as a marker of aggresomes to identify malignant PCs in patient samples. We therefore evaluated the staining pattern in MM paraffin-embedded biopsies using two different antibodies that recognize distinct epitopes of b-catenin. In accordance with the IHC and SEM findings described above, use of either b-catenin antibody revealed a strong perinuclear signal (Supplementary Figure 2) . The occurrence of aggresomes in MM cells was also verified with aggresomal markers ubiquitin and vimentin (Supplementary Figure 3) ; however, we found b-catenin to be a more reliable marker for aggresomes in IHC. We expanded our analysis to include normal (n ¼ 20) and MM BM biopsies (n ¼ 90) using tissue microarrays; PCs were identified with an anti-CD138 antibody. In all normal samples, b-catenin expression in PCs was barely, if at all, detectable (Figure 1f) . Strikingly, greater than 90% of MM cases showed aggresomal b-catenin and nearly all MM cells contained aggresomes (Figure 1f and Supplementary Figure 4) . Thus, our data show that aggresomal b-catenin expression is nearly universal in MM, but absent from normal PCs, which highlights its potential use as a biomarker for malignant PCs.
We then investigated the effect of the proteasome inhibitor bortezomib on b-catenin protein aggregates. 11 We found the number of aggresomes containing b-catenin was significantly increased in MM cells treated with bortezomib compared with untreated cells in vitro (48.2% ± 5.5 vs 23.2% ± 2.9, Po0.0001) (Figure 2a, top) . Moreover, additional b-catenin in aggresomes was also documented in MM xenograft mice (NOD/SCID) treated with bortezomib (Figure 2a, bottom) . Immunoblot (IB) analysis that showed increased amounts of both total and phosphorylated b-catenin in the insoluble cellular fractions containing aggresomes, as well as increased ubiquitinated b-catenin, associated with time of bortezomib treatment (Figure 2b) . We then employed an in vivo SCID-hu model of myeloma that uses human fetal bone chips implanted into NOD/SCID mice to study the effect on b-catenin localization within the endogenous BM microenvironment compared with in vitro cell culture. 12 IFC of the INA-6 cell line grown in vitro showed the presence of b-catenin in perinuclear aggregates in a small proportion of cells (Figure 2c, left) . In contrast, a much larger population of INA-6 myeloma cells grown in SCID-hu mice showed intense staining of b-catenin within aggregates (Figure 2c,  right) . Collectively, these results indicate that b-catenin accumulation in these structures is an active process that is enhanced by disrupted proteasome function and in vivo conditions. Aggresome clearance by autophagy is an important mechanism of removal and can be induced using rapamycin, an inhibitor of mTOR. 13 Treatment of MM cells with rapamycin led to increased staining of the phagosomal marker LC3, an increased number of phagosomes per cell, as well as a significant decrease of b-catenin staining in aggresomes, as assessed by IB, IFC and SEM (Figures 2d  and e) . Moreover, rapamycin treatment led to decreased levels of total and phospho-b-catenin, while activating LC3 (Figure 2d) , suggesting that the decrease in phospho-b-catenin is due in part to phagosomal clearance. In addition, we observed an increased amount of the activated form of the lysosomal marker Cathepsin D following rapamycin treatment, indicating autophagosome --lysosome degradation of b-catenin (Figure 2d ). These results demonstrate that the proteasome --autophagosome --lysosome pathways are all actively involved in modulating b-catenin accumulation in MM aggresomes.
Our findings are in accordance with the fact that the UPS is inherently stressed in MM PCs probably because of the extremely high rate of immunoglobulin synthesis (resulting in the classic monoclonal Ig spike) and degree of somatic hypermutation that increases the probability of protein misfolding. Interestingly, aggresomes have a dynamic signaling role in the cell and can be involved in regulating protein levels by degradation of not only marked or misfolded proteins, but also their more physiological counterparts.
14 It is tempting to speculate that aggresomes in MM may have a similar role, acting as holding stations for b-catenin and thereby contributing to oncogenic signaling. This scenario is consistent with our observation of the coexistence of b-catenin both in aggresomes and in nuclei (Figure 1e) . It is also possible that aggresome formation around the microtubule organizing center and centriole (Supplementary Figure 1b) may interfere with centrosome maturation and spindle assembly during mitosis, and thereby contribute to chromosomal instability that is a hallmark of MM. 15 The mechanisms underlying the formation of aggresomes in most, but not all, myeloma cells within the same tumor remains to be determined, but may reflect a degree of phenotypic and functional cellular heterogeneity. Prospective longitudinal studies of larger numbers of MM patients, its precursor monoclonal gammopathy of undetermined significance, and normal individuals are needed to define the utility of b-catenin in aggresomes as a predictive biomarker or to identify residual disease in BM biopsies to refine assessment of treatment response. Lastly, future drug design could target the proteasome --autophagosome --lysosome system to take advantage of this important aspect of cancer biology for myeloma therapeutics.
